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a b s t r a c t
Rifampicin is a widely used anti-tuberculosis agent. On rare occasions, the drug can cause adverse effects
such as acute renal failure, though most regain complete renal function upon discontinuation of therapy.
The following case report describes a 38 year old Hispanic male presenting with pulmonary tuberculosis
who developed rifampicin-induced renal toxicity. He recovered renal function upon discontinuation of the
medication without the use of corticosteroids.
© 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2. Introduction
Rifampicin is a commonly used and effective drug to treat tuber-
ulosis (TB). Although rare (occurring in 0.1% of patients with tuber-
ulosis), rifampicin-induced acute renal failure may occur as a com-
lication during treatment [1]. Many studies report that this compli-
ation is most common in cases where the drug is re-administered or
sed intermittently [2–4]. The outcome is usually favorable after dis-
ontinuation of the drug, with 96% of patients achieving full recovery
ithin 90 days from onset of renal injury [2]. According to the Ameri-
an Thoracic Society guidelines, physicians are not currently required
o monitor renal function during the course of TB treatment unless
he patient is at high risk for hepatic or renal abnormalities [5]. In the
ollowing report, we describe a patient diagnosed with pulmonary
uberculosis who developed rifampicin-induced renal toxicity while
n anti-tuberculosis therapy.
. Case report
A 38 year old Hispanic male from Central America residing in the
nited States was seen with complaints of productive cough, fever,
ight sweats, weight loss of 50 pounds, anorexia and fatigue. These
ymptoms started three months prior to treatment and gradually
rogressed. The chest radiograph revealed airspace and interstitial
pacities in bilateral upper lobes, more extensive on the left, with
avitation and left tracheal deviation (Fig. 1). The clinic physician,∗ Corresponding author. Tel.: +1 501 661 2886; fax: +1 501 661 2226.
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405-5794/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article undeho was from a tuberculosis-endemic country, suspected tubercu-
osis and immediately referred him to the Arkansas Department of
ealth.
The T Spot TB (Oxford Immunotec Inc., Marlborough, MA) test
as negative, sputum smears were 4+ and the GeneXpert MTB-Rif
ssay (Cepheid Inc., Sunnyvale, CA, USA) was positive and showed
o rifampicin resistance. The patient was initiated on treatment
ith isoniazid, rifampicin, pyrazinamide and ethambutol daily with
irectly observed therapy (DOT) Monday through Friday and self-
dministration on the weekends. A complete metabolic panel (CMP)
btained three days after initiation of therapy showed a total bilirubin
f 0.3 mg/dL, aspartate aminotransferase (AST) of 101 IU/L, alanine
minotransferase (ALT) of 73 IU/L, and creatinine of 0.65 mg/dL. The
ST/ALT values were normal at baseline. The patient denied symp-
oms, but medications were held. The patient denied alcohol use or
se of any other medications (including over the counter hepatotoxic
edications like Tylenol® etc.) and a screen for hepatitis A, B, and C
iruseswas negative. The patient’s liver enzymes returned to baseline
wo weeks after stopping therapy. Pyrazinamide-related hepatotoxi-
ity was suspected and hence he was re-challenged with isoniazid
fter 12 days, rifampin was introduced after 14 days and ethambutol
fter 16 days of stopping medications. The patient noted mild nausea
ithout vomiting and a slight increase in enzymes was noted (AST
02 and ALT 53) eight days after re-introduction of rifampin. Med-
cations were held for 3 days and then restarted. He tolerated this
egimen without toxicity during the next 7 weeks. Culture was pos-
tive for Mycobacterium tuberculosis (MTB) complex, and sensitivities
ater showed pyrazinamide resistance, making us suspect infection
ith M. bovis. Our public health laboratory reports cultures as MTB
omplex (M. tuberculosis, M. bovis, M. microti, M. africanum) and ifr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Patient’s renal function during course of treatment.
Date normal range Renal function Liver function
Creatinine (0.57–1.0) eGFR (>59) BUN (6–20) AST (0–40) ALT (0–32) T. bilirubin (0.0–1.2)
August 18 0.64 111 15 41 28 0.4
29 0.65 123 12 101 73 0.3
September 3 0.54 133 12 118 70 0.3
8 0.5 137 9 68 69 0.3
11 0.5 137 12 53 53 0.3
17 0.64 124 14 46 35 0.4
19 0.54 133 11 44 32 0.6
October 2 0.51 136 9 56 38 0.3
November 10 2.45 32 22 26 10 0.2
12 2.92 26 24 23 10 0.2
December 2 1.66 52 19 29 20 0.2
8 1.61 53 15 40 21 0.3
March 20 1.10 85 15 30 23 0.3
27 1.09 86 13 31 19 0.3
April 3 1.04 91 13 38 24 0.3
24 0.96 100 12 38 23 0.3
June 25 0.91 107 7 31 24 0.4
September 10 0.86 109 13 27 27 0.2
Fig. 1. Chest radiograph at initial presentation.
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sdifferentiation is required, the culture is sent to the Centers for Dis-
ease Control and Prevention (CDC) for further analysis. We did not
pursue this option, but later learned that the genotype of this patient
matched previousM. bovis cases.
A routine surveillance CMP done after 8 weeks on the regi-
men of isoniazid, rifampin and ethambutol showed a total biliru-
bin of 0.2 mg/dL, AST of 26 IU/L, ALT of 10 IU/L, and a creatinine of
2.45 mg/dL with an estimated glomerular ﬁltration rate (eGFR) of
32 (using Modiﬁcation of Diet in Renal Disease-MDRD method). Two
weeks prior, the creatinine was 1.03 mg/dL with an eGFR of 92; the
baseline creatinine was 0.65 mg/dL with an eGFR of 123. All medi-
cations were held. The patient denied symptoms including rash and
fever. Creatinine continued to rise for a week after medications were
stopped, peaking at 3.14 mg/dL with an eGFR of 22 mL/min/1.73. A
complete blood count showedmild anemia (hemoglobin of 10.3 g/dL,
hematocrit 31.3%, a baseline hemoglobin was not available fromur clinic, so we could not assess for rifampin induced hemolysis),
latelets of 361,000/μL, and a normal eosinophils percentage (7%).
rine analysis revealed a speciﬁc gravity of 1.014 (1.005–1.030), and
urine pH of 5.5 (5.0–7.5), but serum pH was not done; appearance
as turbid; protein and glucose were 1+ (the patient has had sev-
ral serum glucose values above normal limits and was referred to
primary care physician for work up of diabetes mellitus. The pa-
ient is uninsured; he has not pursued this work up). White blood
ell esterase and nitrites were negative, urine eosinophils were nega-
ive, urine sodiumwas 70mg/dL and urine creatinine was 97.6 mg/dL
24–392). A fractional excretion of sodium was not done. Urine mi-
roscopy revealed normal counts of white blood cells, red blood cells
nd epithelial cells. Ultrasound of the kidney did not reveal any ab-
ormalities. Creatinine decreased and three weeks after medications
ere discontinued it was at 1.66 with an eGFR of 52. Acute intersti-
ial nephritis due to rifampicin was suspected as the etiology of the
enal toxicity so treatment was restarted with isoniazid, ethambutol
ndmoxiﬂoxacin. The patient’s creatinine sevenmonths after the dis-
ontinuation of rifampicin was 0.91 mg/dL with an eGFR of 107. The
atient has responded well to treatment with improvement in symp-
oms and radiological ﬁndings. Cultures continued to be negative for
TB. He completed therapy in early September 2015 with creatinine
f 0.86 mg/dL and an eGFR of 109 ten months after discontinuation
f rifampicin (Table 1).
As a public health clinic, we have limitations on tests and pro-
edures that we can perform. A renal biopsy and/or kidney-speciﬁc
ests could not be performed due to ﬁnancial and contractual
estrictions.
. Discussion
Although uncommon, rifampin is the most frequent anti-
uberculous medication associated with acute interstitial nephritis
6]. Adverse reactions associated with rifampicin usually occur in pa-
ients who have either previously taken the drug or receive intermit-
ent treatment [7–9]. In a retrospective study done between the years
995 and 2007, 41 patients had a conﬁrmed diagnosis of acute in-
erstitial nephritis. All patients received an intermittent regimen of
nti-tuberculous therapy containing rifampin [9]. This association of
ntermittent or previous exposure is hypothesized to be related to ri-
ampicin’s ability to produce an immune response, which eventually
eads to cell destruction [7]. It is suggested that rifampicin functions
s a molecule that, when bound to proteins, elicits an immune re-
ponse by creating anti-rifampicin antibodies [4]. Consequently, upon
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[e-exposure to rifampicin the patient’s body forms drug antibody
omplexes which lead to cell damage. In a study conducted on 25
atients, it was found that the immune complexes lead to glomerular
ndotheliosis and cellular destruction which results in tubular injury
nd a decrease in renal function [8].
Acute renal injury related to rifampin is usually a clinical diag-
osis. Most reports or series do not include a pathological diagnosis.
eck and Salant note that when renal failure occurs in the setting of
xposure to an offending agent, biopsy is generally not required for
iagnosis [10]. When biopsy is performed the most common ﬁndings
re acute interstitial nephritis or acute tubular necrosis [9,11]. Schu-
ert’s series from South Africa included only patients with biopsy-
roven acute interstitial nephritis who were on chemotherapy for
uberculosis. In this study of 41 patients, acute interstitial inﬁltrate
as present in all cases but acute tubular necrosis was also noted
n 90%. Other less common pathological associations noted with ri-
ampin induced kidney disease include diffuse proliferative crescen-
ic glomerulonephritis [8].
Acute interstitial nephritis is the immune-mediated cause of acute
enal failure associated with rifampin. Although the prognosis of
cute interstitial nephritis is good (1.6% mortality), it remains a se-
ious complication that can progress to Fanconi syndrome, a prox-
mal renal tubule defect leading to malabsorption of phosphorus,
icarbonate, sodium, potassium, glucose, and amino acids, which
esults in various symptoms including bone pain and fracture, fa-
igue, and muscular weakness [12]. Despite the predicted etiology
f our patient’s acute renal failure, rifampin-associated acute inter-
titial nephritis was not proven. Acute kidney injury was noted inci-
entally which may be a common presentation [10]. He did not have
hemore commonly reported symptoms of fever, nausea, vomiting or
levated liver enzymes that some series note [8,9]. Interestingly, he
nitially presented with mild hepatitis and nausea, but these symp-
oms resolved prior to ﬁnding the elevated creatinine. He did not have
osinophilia and eosinophils were not found in the urine. No white or
ed blood cells were found in the urine sediment. A renal biopsy was
ot done.
Although controversial, there is some evidence suggesting that
orticosteroid therapy accelerates renal recovery in patients diag-
osed with drug-induced interstitial nephritis [13]. A retrospective
tudy examined 61 patients with biopsy-proven drug-induced acute
nterstitial nephritis [13]. The patients were divided into two groups,
ith the ﬁrst group (N = 52) receiving steroid treatment and the
econd group (N = 9) receiving no steroid treatment. Of the two
roups, the outcome of the steroid group after treatment was sig-
iﬁcantly better, with the ﬁnal serum creatinine representing a re-
urn to normal renal function. Without treatment, 44% of the non-
teroid group progressed to chronic dialysis. The steroid group was
urther divided into two subgroups: one showed complete recovery
o baseline renal function, while the other showed partial recovery.
he study concluded that there was a correlation between the de-
ay in the onset of steroid treatment and ﬁnal serum creatinine level
13]. Conversely, in another study of 42 patients with acute intersti-
ial nephritis, 26were given steroid therapywhile 16were not treated
6]. The study revealed no signiﬁcant difference in serum creatinineevels between the two groups after one, six, and twelve months of
ollow up.
No randomized trial is available to determine the usefulness of
orticosteroid therapy to guide clinicians. Further observational stud-
es will assist providers making clinical decisions regarding these
atients, but for now the approach is individualized and based on
rovider experience and preference.
The outcome of rifampicin-induced acute renal injury is favorable
n amajority of cases; early detection of this condition should be con-
idered a priority. One study suggests testing patients with previous
xposure to rifampicin for hematuria during the early stages of treat-
ent of tuberculosis in order to detect rifampicin toxicity [9]. If de-
ected early, the drug can be discontinued, thereby preventing further
amage to the patient’s renal system.
. Conclusion
Rifampicin-induced renal toxicity is a rare but serious adverse
ffect amongst patients on anti-tuberculous therapy. Most patients
ecover their renal function upon discontinuation of the offending
gent. The use of corticosteroids is controversial andmore studies are
eeded to demonstrate the clinical beneﬁt of using this therapy.
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